C0229671||serum
C0005516||signature
C2063866||treatment resistant depression
C1269683||major depressive disorder
C1269683||major depressive disorder
C0008976||trials
C0003289||anti-depressants
C0242656||course of disease
C0087111||treatment
C1514892||resistant
C2063866||treatment-resistant depression
C2063866||treatment-resistant depression
C0017337||genes
C0005516||biomarkers
C2063866||treatment-resistant depression
C0872252||high-throughput proteomic platforms
C0205100||peripheral
C0005516||biomarkers
C2063866||treatment-resistant depression
C0449394||staging models
C0449394||Thase and Rush staging model
C0449394||Thase and Rush staging model
C0449394||Maudsley Staging Model
C0449394||Maudsley Staging Model
C0229671||Serum
C0027361||individuals
C1269683||major depressive disorder
C0037813||mass spectrometric-based platforms
C0872318||label-free liquid chromatography mass spectrometry
C0872318||liquid chromatography mass spectrometry
C0020980||multiplex bead based assay
C0872318||LC-MS(E) analysis
C0033684||proteins
C0001349||acute phase response
C0009528||complement activation
C1328723||coagulation
C0449394||staging groups
C0449394||models
C0020980||multiplex bead-based assay
C1168005||TNF-Î± levels
C0449394||Thase and Rush staging model
C0085201||apolipoproteins A-I
C1438565||M
C0052208||F
C0449394||Thase and Rush staging model
C0449394||Maudsley Staging Model
C0243095||findings
C0033684||proteins
C1155000||immune
C0009528||complement activation
C0005516||biomarkers
C0871685||clinicians
C0332167||high-risk
C0449394||staging groups